A middle-aged patient presented for elective embolization of an incidentally found right internal carotid aneurysm. An angiogram was performed, during which the left internal carotid artery was visualized to evaluate a second, small aneurysm. During the embolization of the right internal carotid artery aneurysm, a catheter-induced vasospasm was identified that prompted treatment with intra-arterial verapamil. The procedure was uncomplicated; a postoperative rotational flatpanel computed tomography scan was performed on the angiography table that demonstrated right hemisphere contrast staining. The patient developed a right middle cerebral artery (MCA) syndrome after extubation with repeat cerebral angiography negative for occlusion and magnetic resonance imaging negative for stroke. The patient was observed for 48 hours, during which time the patient had slowly improved. At a six-week follow up visit, the patient had fully recovered. We present an interesting case of a verapamil-induced breakdown of the blood-brain barrier and self-limited right MCA syndrome.
Introduction
A middle-aged patient presented for elective treatment of an incidentally found right internal carotid artery aneurysm (ICA). The patient also was found to have a left anterior choroidal artery aneurysm (see Figure 1 ). Transfemoral cerebral angiography under general anesthesia showed a 2 mm left anterior choroidal artery aneurysm. Moderate, non-flow limiting catheterinduced vasospasm was noted in the right cervical ICA; 10 mg of intra-arterial verapamil was given with improvement. A 4 mm Â 18 mm Pipeline Embolization Device (eV3 Neurovascular, Irvine, CA) was placed without complication (see Figure 2 ). At the conclusion of the case, a flat-panel computed tomography (CT) of the head on the angiography table was performed that demonstrated significant contrast staining of the right cerebral hemisphere (see Figure 3 ).
The patient was noted on extubation to have developed significant left hemiparesis. Immediate repeat cerebral angiography demonstrated patent right ICA vasculature without occlusion. The patient was admitted to the intensive care unit and electroencephalogram (EEG) monitoring was employed. The patient was noted to have progressive neurological decline with aphasia and hemiplegia, with the EEG remaining negative for seizure activity. A limited magnetic resonance imaging (MRI) of the brain was obtained, of diffusion-weighted imaging and MR angiography, which was negative for acute infarction or overt blood products (see Figure 4 ). A repeat CT head 24 hours later demonstrated resolution of contrast staining without hemorrhage or infarction. The patient's blood pressure was maintained at baseline or slightly lower.
After 48 hours, the patient slowly improved without further interventions, and was discharged home four days after the procedure. At six-week follow-up, the patient had completely recovered and was neurologically intact.
Verapamil is a calcium channel blocker and vasodilator that is commonly used in the treatment of medically refractory symptomatic vasospasm following subarachnoid hemorrhage (SAH), 1 and may also be used in the treatment of catheter-associated vasospasm. There are known side effects of intra-arterial (IA) verapamil infusion that include symptomatic hypotension, bradycardia, and elevated intracranial pressure; 1 there have also been rare reports of seizure following verapamil infusion. 2, 3 In these circumstances, the proposed etiology was attributed to a direct toxic effect of the drug on a metabolically challenged, ischemic brain 3 or possibly due to rapid reperfusion of an ischemic brain. 2 In one case report of seizure following verapamil infusion, a CT head was normal, while in the second case CT of the head findings following verapamil infusion were not reported. This finding is significantly different from our reported case, when the post-procedure CT demonstrated extensive contrast staining in the right cerebral hemisphere.
Recently, the literature has proposed that verapamil may actually be co-administered to patients with drugresistant epilepsy or status epilepticus with promising results. 4 There is little evidence to suggest verapamil administered systemically may trigger seizure; indeed, it may be used as an adjunct to treat seizures because of its ability to ameliorate the efflux of antiepileptic medications by multidrug transporters. However, IA infusion, and the rate of the infusion, of verapamil directly into cerebral vasculature may trigger other responses. Fasudil has been shown to trigger seizures during IA infusion for treatment of cerebral vasospasm, with a higher incidence of seizure following more rapid infusion of the medication. 5 This mechanism may also play a role in the suggested report of verapamil-associated seizures.
There have been reports of blood-brain barrier (BBB) disruption following the administration of papaverine for cerebral vasospasm. 6 Papaverine acts by inhibiting cyclic adenosine monophosphate, which has been shown to disrupt the BBB and lead to the extravasation of blood and contrast agents. 7 Fasudil acts through inhibition of Rho-kinase, leading to subsequent vasodilation and potentially BBB disruption. 8 A similar mechanism may have been at play in our case, with verapamil acting through L-type calcium channel blockage, vasodilation, and BBB breakdown, which led to the contrast extravasation. 9 It has also been shown that verapamil alters brain glucose content and interacts with P-glycoprotein-mediated transportation, which may further contribute to BBB disruption. 10, 11 It is most likely that the hyperdensity observed was contrast staining and not extravasated blood products, since contrast resolves within 19-24 hours. 12 Our patient had a repeat CT of the head that demonstrated complete resolution of the hyperdensity, thereby proving there was no hemorrhage.
Hyper-perfusion may also be seen following flow diverter use, such as with the Pipeline Embolization Device. When Pipeline Embolization Devices are placed, there are multiple significant changes that occur in the hemodynamics of the patient, including increases in ipsilateral middle cerebral artery (MCA) flow and wall shear stress. 13 Hyper-perfusion syndrome is thought to occur because of rapid reperfusion of chronically hypo-perfused parenchyma with subsequent impaired autoregulation, 14 with clinical findings of headache, hypertension, seizures, and potentially neurological deficit, and imaging findings remaining negative for acute changes both on CT and MRI following flow diverter placement. 15 Hyper-perfusion is unlikely to be the cause of the patient's neurologic decline as the patient did not exhibit hypertension, seizure, or headache. Further, there was right hemispheric contrast staining on the post-procedure CT of the head, which is not seen in hyper-perfusion syndrome. Further, there was no cerebral edema identified, which may be seen in hyper-perfusion syndromes.
In our patient, the symptoms likely were caused by a combination of BBB breakdown as well as hyperperfusion secondary to increased blood flow following administration of the verapamil and subsequent Pipeline Embolization Device deployment. It is possible that our patient developed seizure secondary to verapamil infusion, but this is unlikely for many reasons, including (a) there was radiographic evidence of contrast staining on the postoperative CT scan, (b) the symptoms progressed throughout the following 24 hours, and (c) EEG findings during the patient's progressive neurological decline were negative for seizure.
Another possibility that is similarly unlikely is that the patient developed diffuse SAH secondary to intraprocedural rupture of the aneurysm or intracranial vasculature. This is unlikely as there was no observed perforation of vasculature, nor was there contrast extravasation noted on angiography (see Figure 2 ). Additionally, the patient's symptoms were not typical of SAH and the hyperdensity on CT had resolved in 24 hours, confirming the hyperdensity to be contrast staining. There was also a significant concern that the patient had a cerebral infarction, but this too is unlikely as the patient had an immediate cerebral angiogram that demonstrated patent vasculature, the MRI of the brain following the procedure was negative for acute infarction, and the patient has since made a full recovery.
The prompt evaluation of patients presenting with new neurologic deficits and the exclusion of serious events such as ischemic stroke, hemorrhage, and seizure is key. This diagnosis should be one of exclusion, and may be made by obtaining emergent CT of the head to rule out hemorrhage, MRI of the brain to rule out acute infarction, and EEG to evaluate for seizure. Prevention revolves around maintaining strict blood pressure control, and avoidance of major drug-drug interactions that may be identified preoperatively. Verapamil affects P-glycoprotein-mediated transport, and thus may affect transport and permeability at the BBB.
Thus, we conclude that the likely etiology of the constellation of findings in our patient was caused primarily by BBB breakdown, combined with a hyperperfusion-type syndrome and transient elevation of intracranial pressure secondary to vasodilation and increased cerebral blood flow. To our knowledge, this is the first report of verapamil causing diffuse contrast staining of the cerebrum coupled with a transient stroke-like syndrome after infusion for the treatment of vasospasm.
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